The antileukemic activity of modified fibrinogen-methotrexate conjugate

► Covalent conjugation of methotrexate with fibrinogen was performed. ► Conjugate is more active against leukemia in the in vivo model vs free drug. ► Partial hydrolysis of fibrinogen provides a promising anti-cancer drug carrier.